Exeliom Biosciences
- | Biotech or pharma, therapeutic R&D
Exeliom Biosciences is a clinical-stage biotech company developing a first-in-class NOD2-dependent immune modulator for oncology, immunology, and infectious diseases. Our lead candidate, EXL01, a NOD2 hyperagonist from gut microbiota, is designed to enhance immune-checkpoint inhibitors and improve outcomes in solid tumors.
EXL01 is currently in three Phase I/II studies for gastric cancer, NSCLC, and HCC, with results expected in two years. A fourth trial in RCC will launch in the U.S. in 2025. Beyond oncology, EXL01 is in Phase II studies for Crohn's disease and preventing recurrent C. difficile infections.
Exeliom seeks additional funding to advance EXL01 to Phase III readiness while expanding its investor syndicate of five established backers.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}